[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK174970B1 - Leukæmi-hæmmende faktor (LIF), DNA der koder herfor, værtsceller med DNA samt fremgangsmåde til fremstilling af LIF - Google Patents

Leukæmi-hæmmende faktor (LIF), DNA der koder herfor, værtsceller med DNA samt fremgangsmåde til fremstilling af LIF Download PDF

Info

Publication number
DK174970B1
DK174970B1 DK198904831A DK483189A DK174970B1 DK 174970 B1 DK174970 B1 DK 174970B1 DK 198904831 A DK198904831 A DK 198904831A DK 483189 A DK483189 A DK 483189A DK 174970 B1 DK174970 B1 DK 174970B1
Authority
DK
Denmark
Prior art keywords
lif
cells
murine
human
amino acid
Prior art date
Application number
DK198904831A
Other languages
Danish (da)
English (en)
Other versions
DK483189A (da
DK483189D0 (da
Inventor
Donald Metcalf
Nicholas Martin Gough
Douglas James Hilton
David Paul Gearing
Julie Ann King
Edouard Collins Nice
Nicos Anthony Nicola
Richard John Simpson
Tracy Ann Willson
Original Assignee
Amrad Corp Ltd A Corp Of The S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrad Corp Ltd A Corp Of The S filed Critical Amrad Corp Ltd A Corp Of The S
Publication of DK483189D0 publication Critical patent/DK483189D0/da
Publication of DK483189A publication Critical patent/DK483189A/da
Application granted granted Critical
Publication of DK174970B1 publication Critical patent/DK174970B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK198904831A 1987-04-02 1989-10-02 Leukæmi-hæmmende faktor (LIF), DNA der koder herfor, værtsceller med DNA samt fremgangsmåde til fremstilling af LIF DK174970B1 (da)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
AUPI120987 1987-04-02
AUPI120987 1987-04-02
AUPI331787 1987-07-24
AUPI331787 1987-07-24
AUPI490387 1987-10-15
AUPI490387 1987-10-15
AUPI600587 1987-12-21
AUPI600587 1987-12-21
AU8800093 1988-03-31
PCT/AU1988/000093 WO1988007548A1 (en) 1987-04-02 1988-03-31 Leukaemia-inhibitory factor

Publications (3)

Publication Number Publication Date
DK483189D0 DK483189D0 (da) 1989-10-02
DK483189A DK483189A (da) 1989-12-04
DK174970B1 true DK174970B1 (da) 2004-04-05

Family

ID=27424196

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198904831A DK174970B1 (da) 1987-04-02 1989-10-02 Leukæmi-hæmmende faktor (LIF), DNA der koder herfor, værtsceller med DNA samt fremgangsmåde til fremstilling af LIF

Country Status (15)

Country Link
US (5) US5187077A (pt)
EP (1) EP0285448B1 (pt)
JP (2) JP2682858B2 (pt)
KR (1) KR0121324B1 (pt)
CA (1) CA1341581C (pt)
DE (1) DE3888379T2 (pt)
DK (1) DK174970B1 (pt)
ES (1) ES2061643T3 (pt)
FI (1) FI113372B (pt)
HK (1) HK33695A (pt)
IL (1) IL85961A (pt)
NO (1) NO178265C (pt)
PT (1) PT87133B (pt)
SG (1) SG11795G (pt)
WO (1) WO1988007548A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
JP2740320B2 (ja) * 1988-08-04 1998-04-15 アムラド・コーポレイション・リミテッド 胚幹細胞のインビトロ増殖
US20030032178A1 (en) * 1988-08-04 2003-02-13 Williams Robert Lindsay In vitro propagation of embryonic stem cells
WO1990002183A1 (en) * 1988-08-18 1990-03-08 Genetics Institute, Inc. Production of a novel lymphokine exhibiting differentiation inhibitory activity
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
AU5104390A (en) * 1989-02-08 1990-09-05 Uab Research Foundation Antiproliferation factor
ATE138267T1 (de) * 1989-11-24 1996-06-15 Univ Monash Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen
DE69119759T2 (de) 1990-03-20 1997-01-16 Amrad Corp Ltd Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
EP0620736B1 (en) * 1991-12-24 2001-03-07 Amrad Corporation Limited Use of leukemia inhibiting factor (lif) for the treatment of tumours and sarcomas
US5916871A (en) * 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
EP0651769A4 (en) * 1992-07-01 1996-05-08 Amrad Corp Ltd PROTEIN BINDING THE LEUKEMIA-INHIBITING FACTOR.
EP0746569A4 (en) * 1993-02-03 1999-03-24 Amrad Corp Ltd DETERMINANT FOR FIXING THE RECEPTOR FROM THE LEUKEMIA INHIBITION FACTOR
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
US5849991A (en) 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
JPH09508277A (ja) * 1994-01-27 1997-08-26 ブレサゲン リミテッド ヒト異種移植における超急性拒絶の管理のための物質及び方法
US6184370B1 (en) * 1994-02-03 2001-02-06 Amrad Corporation Limited Receptor-binding determinant from leukaemia inhibitory factor
US5824838A (en) * 1996-05-09 1998-10-20 Cedars-Sinai Medical Center Transgenic mouse model for pituitary disorders associated with LIF overexpression and/or GH underexpression, and its use for testing therapeutic drugs for the conditions
WO1998004587A1 (en) * 1996-07-25 1998-02-05 New York University POLYPEPTIDE COFACTORS THAT MEDIATE α-TUBULIN AND β-TUBULIN FOLDING
US6156729A (en) 1997-10-15 2000-12-05 California Institute Of Technology Leukemia inhibitory factor for use in modulating inflammation and pain
AUPP053197A0 (en) * 1997-11-26 1997-12-18 Amrad Operations Pty. Limited Compositions
JP2002519387A (ja) 1998-07-06 2002-07-02 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 体外受精のための組成物および方法
US20040234539A1 (en) * 1999-11-03 2004-11-25 Powderject Research Limited Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
WO2001096866A1 (en) * 2000-06-14 2001-12-20 Vistagen, Inc. Toxicity typing using liver stem cells
MXPA02006118A (es) 2000-10-20 2004-08-23 Amylin Pharmaceuticals Inc Tratamiento de la invernacion del miocardio y cardiopatia diabetica con un peptido glp-1.
US7604807B2 (en) * 2000-12-01 2009-10-20 Auburn University Use of pullulan to isolate and preserve biological material
US20040121460A1 (en) * 2001-01-24 2004-06-24 Lumelsky Nadya L Differentiation of stem cells to pancreatic endocrine cells
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
WO2003027247A2 (en) 2001-09-24 2003-04-03 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
JP4408371B2 (ja) 2001-12-21 2010-02-03 トロンボジェニクス・ナムローゼ・フエンノートシャップ 生殖細胞系伝達能力を有する胚性幹（ｅｓ）細胞のインビトロの誘導および培養のための組成物
GB0220145D0 (en) * 2002-08-30 2002-10-09 Thromb X Nv Novel compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability
US20050010231A1 (en) * 2003-06-20 2005-01-13 Myers Thomas H. Method and apparatus for strengthening the biomechanical properties of implants
FR2870739B1 (fr) * 2004-05-26 2008-05-16 Oreal Utilisation du lif en cosmetique et en dermatologie
FR2870854B1 (fr) * 2004-05-26 2010-12-31 Oreal Utilisation du lif en ingenierie cellulaire et tissulaire
US20050277124A1 (en) * 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
US20070292949A1 (en) * 2006-06-20 2007-12-20 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
US20130059375A1 (en) 2010-04-02 2013-03-07 Riken Method for preparing es cells
KR101434739B1 (ko) * 2012-08-23 2014-09-01 울산대학교 산학협력단 인간 ＰＤＩｂ´ａ´태그를 이용한 생물학적 활성을 가진 인간 ＬＩＦ 재조합 단백질의 대장균 내 발현 및 정제방법
RU2690352C2 (ru) 2013-02-20 2019-05-31 Регенерон Фармасютикалс, Инк. Генетическая модификация крыс
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
US20210046193A1 (en) * 2018-03-02 2021-02-18 University Of Florida Research Foundation, Incorporated Drug stabilized therapeutic transgenes delivered by adeno-associated virus expression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578355A (en) * 1983-01-12 1986-03-25 The United States Of America As Represented By The Department Of Health And Human Services Plasmid cloning vector pAS1
JPS60105621A (ja) * 1983-11-14 1985-06-11 Agency Of Ind Science & Technol 細胞の分化誘導作用を有する生理活性物質およびその製法
US4616079A (en) * 1984-08-24 1986-10-07 Imreg, Inc. Immunoamplifiers and processes for the extraction thereof
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
JPS62223126A (ja) * 1986-03-25 1987-10-01 Sankyo Co Ltd 血液幹細胞成長因子
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
JPS6448197A (en) * 1987-08-19 1989-02-22 Sanden Corp Goods takeoff port unit for vending machine
JPH01148197A (ja) * 1987-12-04 1989-06-09 Green Cross Corp:The 腫瘍細胞障害因子

Also Published As

Publication number Publication date
FI894613A0 (fi) 1989-09-29
EP0285448B1 (en) 1994-03-16
IL85961A (en) 1997-03-18
DE3888379T2 (de) 1994-07-28
FI894613A (fi) 1989-09-29
EP0285448A3 (en) 1990-08-29
HK33695A (en) 1995-03-17
NO885339L (no) 1989-02-01
JPH07138292A (ja) 1995-05-30
US5443825A (en) 1995-08-22
US5427925A (en) 1995-06-27
US5187077A (en) 1993-02-16
CA1341581C (en) 2008-09-30
EP0285448A2 (en) 1988-10-05
KR890700610A (ko) 1989-04-26
PT87133B (pt) 1992-07-31
US6261548B1 (en) 2001-07-17
DE3888379D1 (de) 1994-04-21
DK483189A (da) 1989-12-04
SG11795G (en) 1995-06-16
WO1988007548A1 (en) 1988-10-06
ES2061643T3 (es) 1994-12-16
PT87133A (pt) 1988-04-01
NO178265C (no) 1996-02-21
NO885339D0 (no) 1988-11-30
KR0121324B1 (ko) 1997-11-28
JPH01502985A (ja) 1989-10-12
JP2682858B2 (ja) 1997-11-26
DK483189D0 (da) 1989-10-02
NO178265B (no) 1995-11-13
FI113372B (fi) 2004-04-15
US5750654A (en) 1998-05-12
JP2721123B2 (ja) 1998-03-04

Similar Documents

Publication Publication Date Title
DK174970B1 (da) Leukæmi-hæmmende faktor (LIF), DNA der koder herfor, værtsceller med DNA samt fremgangsmåde til fremstilling af LIF
Gearing et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF).
JP3115318B2 (ja) Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
JP3507507B2 (ja) 非免疫原性ペプチドを介して結合されたインターフェロン―αと免疫グロブリンとのハイブリッド
FI82712B (fi) Foerfarande foer framstaellning av ett humant moget leukocytinterferon.
DK175583B1 (da) DNA-sekvenser kodende for interleukin-4-receptorer, RNA komplementært til disse, rekombinant ekspressionsvektor omfattende disse DNA-sekvenser, værtscelle transfekteret med denne vektor, fremgangsmåde til fremstilling af.
US5108910A (en) DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
JP2553829B2 (ja) 組換えコロニー刺激因子−１
FI103987B (fi) Interleukiini-7
JPH01501283A (ja) 新規な型のコロニー刺激因子―１
JP3217698B2 (ja) 成熟ヒト インターロイキン１タンパク質
DE3687761T2 (de) Herstellung des menschlichen von-willebrand-faktors durch rekombinante dns.
JPS63301798A (ja) コロニー刺激因子誘導体
JPH04500508A (ja) 非グリコシル化　ヒト　インターロイキン―３　組成物
AU609128B2 (en) Leukaemia-inhibitory factor
JPS6361960B2 (pt)
US20030004098A1 (en) Leukaemia inhibitory factor
IE920424A1 (en) Method of inhibiting replication of hiv in macrophages
KR0121322B1 (ko) 백혈병 억제 인자 제조를 위한 재조합 dna 분자 및 숙주 세포
NO179210B (no) Fremgangsmåte for fremstilling av et LIF polypeptid, rekombinant DNA molekyl som koder for LIF polypeptidet samt vertscelle for å uttrykke dette
JPS62502305A (ja) ポリペプチドの産生を向上する方法
NZ224105A (en) Leukaemia inhibitory factor
HU207342B (en) Process for producing human or mouceleukemie inhibitor factor /lif/ and pharmaceutical compositions of lif activity and process for purifying lif after or without glycozilation
CA1340264C (en) Recombinant dna expression of novel diuretic/vasodilator compounds
FI82714B (fi) Foerfarande foer framstaellning av en transformerad stam av e.coli, som foermaor expressera ett humant moget leukocytinterferon.

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
AHS Application shelved for other reasons than non-payment
PUP Patent expired